Welcome to our dedicated page for MEDEXUS PHARMS news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on MEDEXUS PHARMS stock.
MEDEXUS PHARMS INC (MEDXF) is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. The company focuses on therapeutic areas such as oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Recent achievements include the approval of IXINITY for pediatric patients under 12 years of age with hemophilia B and the acceptance of treosulfan's New Drug Application for review by the FDA. MEDXF is dedicated to enhancing patient care and quality of life through its products.
Medexus Pharmaceuticals has expanded its medical affairs team in anticipation of launching treosulfan, an innovative agent for patients receiving allo-HSCT. This proactive measure aims to ensure a successful launch by the scheduled PDUFA date in August 2021. Treosulfan, which showed a 64.0% two-year event-free survival rate in clinical trials, is projected to become the new standard of care, filling a significant market gap. The team includes experienced leaders like Keith Steward and J. Lynn Bass, enhancing Medexus's capability to engage with key stakeholders.
Medexus Pharmaceuticals (MEDXF) has announced the immediate availability of Triamcinolone Hexacetonide (TH) Injectable Suspension in the U.S. through the FDA’s Drug Shortage program. This drug is indicated for treating various inflammatory joint diseases. Medexus is collaborating with Ethypharm to expedite the data necessary for filing an Abbreviated New Drug Application (ANDA). The company aims to establish a solid portfolio in rare diseases, focusing on innovative healthcare products and expanding its commercial presence across North America.
Medexus Pharmaceuticals, listed as OTCQX: MEDXF, announced their participation in the LD Micro Invitational XI investor conference from June 8-10, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on June 8 at 12:30 p.m. EST. The conference provides a platform for investors to gain insights into Medexus's growth strategy in the rare disease market. Medexus focuses on innovative therapies for auto-immune diseases, hematology, and allergies, with prominent products like Rasuvo™, IXINITY®, and Rupall®.
Medexus Pharmaceuticals announced its participation in the Sidoti & Company Virtual Microcap Conference from May 19 to May 20, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on May 19 at 9:15 AM Eastern Time, with a live webcast available for replay. The company will also hold one-on-one virtual meetings with interested investors. Medexus focuses on innovative and rare disease treatments, particularly in auto-immune disease, hematology, and allergy, featuring products like Rasuvo™ and IXINITY®.
Medexus Pharmaceuticals announced participation in upcoming investor conferences, including the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, and the Stifel 2021 Canada Cross Sector Insight Conference on April 21, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present corporate updates to engage with investors. Medexus focuses on innovative treatments for rare diseases, providing products like Rasuvo™ and IXINITY® for auto-immune diseases and hemophilia. The company aims to enhance its market presence and investor relationships through these events.
Medexus Pharmaceuticals has announced that all non-executive directors will receive restricted share units (RSUs) instead of cash fees for 2021. This decision aligns with the Company’s 2018 omnibus equity incentive plan. The RSUs will vest immediately, allowing directors to acquire common shares at $0.01 each. Medexus focuses on developing innovative products for rare diseases, particularly in auto-immune diseases and hematology, with notable products like Rasuvo™ and IXINITY®. The Company's strategic move to offer RSUs may enhance alignment with shareholder interests.
Medexus Pharmaceuticals Inc. (OTCQX: MEDXF) announced that CEO Ken d’Entremont and CFO Roland Boivin will hold 1x1 meetings with investors at the 33rd Annual Roth Conference from March 15-17, 2021. This virtual event includes small group meetings, analyst-led fireside chats, and on-demand company presentations. Medexus focuses on innovative treatments for rare diseases, including Rasuvo™ for rheumatoid arthritis, IXINITY® for Hemophilia B, and Rupall® for allergies. The company aims to provide high-quality healthcare products through its core values.
Medexus Pharmaceuticals reported record fiscal third-quarter revenue of $31.5 million for the three months ending December 31, 2020, a 94% increase from $16.2 million year-over-year. Adjusted EBITDA rose to $5.1 million from $0.7 million. Despite this revenue growth, the company experienced a net loss of $17.1 million, attributed primarily to a significant increase in the fair value of derivative instruments. The company completed a $32.5 million financing and acquired licensing rights for treosulfan, aiming to boost future growth.
Medexus Pharmaceuticals announced the commercial launch of Gleolan® in Canada, an imaging agent for brain tumor surgery, previously available only through the Health Canada Special Access Program. Gleolan enhances visualization of malignant tissue during surgery for Grades III and IV gliomas, significantly increasing complete tumor resection rates. A pivotal Phase III study showed 65% complete resection with Gleolan versus 36% without, and 41% of patients were progression-free after six months. The launch aims to improve surgical outcomes for the 1,000 Canadians diagnosed with glioblastoma annually.
Medexus Pharmaceuticals plans to host a conference call at 8:00 AM ET on March 2, 2021, to discuss its financial results for the third quarter of fiscal 2021, which ended on December 31, 2020. The company will file its financial statements on March 1, 2021. Investors can access the call via phone or through a webcast. Medexus focuses on orphan and rare diseases, providing products like Rasuvo™ and IXINITY® for conditions including rheumatoid arthritis and Hemophilia B. For further insights, the company promotes its commitment to quality, innovation, and customer service.
FAQ
What is the current stock price of MEDEXUS PHARMS (MEDXF)?
What is the market cap of MEDEXUS PHARMS (MEDXF)?
What is the focus of MEDEXUS PHARMS INC?
What recent achievements has MEDEXUS PHARMS INC had?
What sets MEDEXUS PHARMS INC apart?
